Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2020-09-29 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
ELECTION OF LANGUAGE AND MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS
Regulatory Filings Classification · 95% confidence The document is an announcement from Ocumension Therapeutics regarding the election of language and means of receipt of future corporate communications for shareholders. It references compliance with Listing Rules and Articles of Association, and details arrangements for shareholders to elect how they receive corporate communications such as annual reports, interim reports, notices of meetings, circulars, and proxy forms. The document does not contain any financial data, results, or detailed reports itself, but rather informs shareholders about options for receiving such documents in the future. It is a regulatory announcement about communication preferences and distribution methods, not a financial report or meeting material. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-09-29 English
2020 Interim Report
Interim / Quarterly Report Classification · 100% confidence The document is titled '2020 INTERIM REPORT' and contains detailed financial statements such as the condensed consolidated statement of profit or loss, financial position, changes in equity, and cash flows. It also includes management discussion and analysis, business review, financial review, and notes to the financial statements. The presence of unaudited financial data for the six months ended June 30, 2020, and 2019, confirms this is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-09-29 English
VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF OT-1001 (ZERVIATE) APPROVED IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of Ocumension Therapeutics regarding the approval of a phase III clinical trial for a drug (OT-1001/ZERVIATE) in China. It is an announcement of a clinical development milestone, not a financial report, regulatory filing, or management change. The document is relatively short (3435 characters) and does not contain financial data, earnings, or detailed management discussion. It is not an AGM material, voting result, or capital update. It is a corporate announcement about a product development event. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories.
2020-09-22 English
ANNOUNCEMENT ACQUISITION OF 100% EQUITY INTEREST IN SUZHOU XIAXIANG AND CHANGE IN USE OF PROCEEDS FROM THE LISTING
Capital/Financing Update Classification · 95% confidence The document is an announcement by Ocumension Therapeutics regarding the acquisition of 100% equity interest in Suzhou Xiaxiang and a change in the use of proceeds from the company's IPO listing. It references the prospectus and listing on the Hong Kong Stock Exchange, discusses the acquisition details, and changes in capital allocation. There are no financial statements or detailed financial performance data presented, nor is this a transcript, report, or regulatory certification. The content is clearly about a corporate acquisition and capital use update, which fits the category of Capital/Financing Update (CAP). The document length is 7291 characters, which is substantive and not a mere announcement of a report publication. Therefore, the classification is CAP with high confidence.
2020-09-11 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/08/2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities issued during the month, including confirmations related to compliance with listing rules and legal requirements. This type of document is a regulatory filing reporting monthly movements in securities and share capital, not a full financial report, earnings release, or management discussion. It is not an announcement of a report but a periodic regulatory disclosure. Therefore, it fits best under 'Regulatory Filings (RNS)' as a general regulatory announcement that does not fit other specific categories.
2020-09-03 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2020' and contains detailed unaudited condensed consolidated interim financial results, including revenue, loss before tax, and non-IFRS adjusted net loss for the six-month period. It also includes a Management Discussion and Analysis section with business overview, product portfolio, and progress on drug candidates. The document length is about 15,000 characters, indicating it is a substantive report rather than a brief announcement. The content includes actual financial data and analysis for a period shorter than a full fiscal year (six months), which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of the report or a certification, but the report itself with financial statements and management commentary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2020
2020-08-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.